Renaissance Technologies LLC Boosts Holdings in Protara Therapeutics, Inc. (NASDAQ:TARA)

Renaissance Technologies LLC lifted its stake in Protara Therapeutics, Inc. (NASDAQ:TARA) by 77.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 150,400 shares of the company’s stock after buying an additional 65,800 shares during the period. Renaissance Technologies LLC owned approximately 0.73% of Protara Therapeutics worth $313,000 at the end of the most recent quarter.

Separately, Oppenheimer & Co. Inc. purchased a new position in shares of Protara Therapeutics in the 1st quarter valued at $40,000. 38.13% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Protara Therapeutics

In other news, major shareholder Opaleye Management Inc. sold 32,600 shares of the firm’s stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $1.71, for a total value of $55,746.00. Following the completion of the sale, the insider now owns 51,500 shares in the company, valued at approximately $88,065. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders sold 80,488 shares of company stock worth $152,522. Company insiders own 12.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $23.00 price objective on shares of Protara Therapeutics in a research report on Thursday, August 8th. Oppenheimer lowered their price objective on shares of Protara Therapeutics from $30.00 to $25.00 and set an “outperform” rating on the stock in a research report on Monday, August 12th.

Protara Therapeutics Stock Performance

Shares of Protara Therapeutics stock opened at $1.68 on Friday. Protara Therapeutics, Inc. has a 1 year low of $1.04 and a 1 year high of $5.24. The company has a market capitalization of $34.66 million, a P/E ratio of -0.53 and a beta of 1.82. The company’s fifty day moving average is $1.91 and its two-hundred day moving average is $2.48.

Protara Therapeutics (NASDAQ:TARA) last released its earnings results on Tuesday, August 6th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.37. As a group, equities analysts expect that Protara Therapeutics, Inc. will post -2.96 earnings per share for the current year.

Protara Therapeutics Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.